Patents by Inventor Ahmed Esmat

Ahmed Esmat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemotherapeutic oxazolone derivatives and pharmaceutical compositions thereof
    Patent number: 11220485
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: January 11, 2022
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • Anticancer compounds, pharmaceutical compositions thereof, and a method of treating cancer
    Patent number: 11180458
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: November 23, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • Anti-cancer compounds having oxazolone derivation
    Patent number: 11174233
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: November 16, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • CHEMOTHERAPEUTIC OXAZOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20210340110
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • ANTICANCER COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND A METHOD OF TREATING CANCER
    Publication number: 20210139434
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: November 12, 2019
    Publication date: May 13, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Ahmed ESMAT, Farid AHMED, Azizah M. MALEBARI, Ashraf B. ABDEL-NAIM, Thikryat NEAMATALLAH
  • Pharmaceutical composition and method of treating cancer
    Patent number: 10844022
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: November 24, 2020
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah